R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.

Slides:

Advertisements

Similar presentations

Palumbo A et al. Proc ASH 2013;Abstract 536.

Advertisements

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

Facon T et al. Proc ASH 2013;Abstract 2.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

1Coiffier B et al. Proc ASH 2010;Abstract 114.

Supervisor: Vs 楊慕華醫師 Presenter: CR 周益聖醫師 N Engl J Med 2012;367:

Casulo C et al. Proc ASH 2013;Abstract 510.

Palumbo A et al. Proc ASH 2012;Abstract 446.

LaCasce A et al. Proc ASH 2014;Abstract 293.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.

Radioimmunotherapy as Consolidation in MCL (Mantle Cell Lymphoma) — 8 Years Follow-Up of a Prospective Phase 2 Polish Lymphoma Research Group Study Jurczak.

Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.

A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

Ruan J et al. Proc ASH 2013;Abstract 247.

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.

The Bruton’s Tyrosine Kinase Inhibitor PCI is Highly Active as Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary.

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

1 Flinn I et al. Proc ICML 2013;Abstract 084.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Results from a Randomized Phase III Trial of Decitabine versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed.

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.

Rituximab Maintenance After Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy plus Rituximab vs CHOP Chemotherapy plus Iodine-131-Tositumomab for the Treatment.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Attal M et al. Proc ASH 2010;Abstract 310.

Mateos MV et al. Proc ASH 2013;Abstract 403.

Jabbour E et al. Proc ASH 2015;Abstract 83.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Kahl BS et al. Proc ASH 2011;Abstract LBA-6.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Vitolo U et al. Proc ASH 2011;Abstract 777.

Fowler NH et al. Proc ASH 2011;Abstract 99.

Salles GA et al. Proc ASCO 2010;Abstract 8004.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Zaja F et al. Proc ASH 2010;Abstract 966.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Advani RH et al. Proc ASH 2011;Abstract 443.

Presentation transcript:

R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH 2011;Abstract 439.

Kluin-Nelemans HC et al. Proc ASH 2011;Abstract 439. Study Schema Eligibility (N = 560) Newly diagnosed MCL >60 years PS 0-2 Stages II-IV IFNa or Peg-IFN maintenance until progression (n = 161) R maintenance q2mo until progression (n = 155) R = rituximab; CR = complete response; PR = partial response CR, PR (n = 316) R 8 x R-CHOP (n = 279) 6 x R-FC (n = 281) R

Efficacy of R-CHOP vs R-FC Induction Kluin-Nelemans HC et al. Proc ASH 2011;Abstract 439. R-CHOP (n = 232) R-FC (n = 243)p-value Overall response rate CR/CRu PR PD 87% 50% 37% 5% 78% 53% 25% 14% Median time to treatment failure 28 mo26 mo0.52 Median overall survival77 mo43 mo Median follow-up 36 months

R-CHOP vs R-FC Toxicity With permission from Kluin-Nelemans HC et al. Proc ASH 2011;Abstract 439. Hb p = Lympho p = WBC p = Neutrophils p = 0.25 Platelets p < Mucositis p = Cardiac function p = 0.70 Pulm function p > 0.99 Neuropathy p < Alopecia p < Infections p = Febrile neutropenia p = R-CHOP Grade 3-4 R-FC Grade 3-4 R-CHOP Grade 1-2 R-FC Grade 1-2

Efficacy of Rituximab vs IFN Maintenance Kluin-Nelemans HC et al. Proc ASH 2011;Abstract 439. Rituximab maintenance (n = 139) IFN maintenance (n = 128) Hazard ratiop-value Remission duration77 mo26 mo Four-year overall survival 77%65%—0.15 Four-year overall survival related to induction regimen After R-CHOP87%61%— After R-FC70% —0.5 Median follow-up 36 months

Toxicity of IFN and Rituximab With permission from Kluin-Nelemans HC et al. Proc ASH 2011;Abstract 439. IFN Grade 3-4 R Grade 3-4 IFN Grade 1-2 R Grade 1-2 Hb p = 0.94 Lympho p = WBC p = Neutrophils p = 0.20 Platelets p = Depression p = 0.16 Fatigue p < Infections p = 0.022

Author Conclusions Induction therapy with R-CHOP versus R-FC favors R-CHOP with more overall responses and less toxicity. Rituximab maintenance doubles the remission duration in patients responding to initial therapy. Patients pretreated with R-CHOP and maintained on rituximab have a 4-year overall survival of 87%. Long-term rituximab has low toxicity. R-CHOP followed by maintenance rituximab should become the gold standard to which new induction regimens are compared. Kluin-Nelemans HC et al. Proc ASH 2011;Abstract 439.

Investigator Commentary: R-CHOP versus R-FC Followed by Maintenance with Rituximab versus IFN in Elderly Patients with Mantle-Cell Lymphoma (MCL) Treatment of MCL in elderly patients is a challenge. This study reported that R-CHOP followed by rituximab maintenance is much better than R-FC followed by maintenance with rituximab or IFN. This was an older study — IFN is not being used any more. R-CHOP followed by rituximab maintenance should be the treatment approach for elderly patients with MCL. For older patients with MCL who do not receive transplants, I do administer rituximab maintenance. Interview with Stephanie A Gregory, MD, January 11, 2012